Printer Friendly Version View printer-friendly version
<< Back
Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology
Commercializing Core Cell-free DNA Technology Beyond Reproductive Health

SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its emerging businesses in renal transplantation and oncology, during an investor call on June 27, 2018.

Date:

June 27, 2018

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In US/Canada:

(877) 823-0171

Live Dial-In US/ Canada/


International:

(617) 500-6932

Conference ID:

9888083

Webcast Link:

https://edge.media-server.com/m6/p/rq5xvav6

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

A webcast replay will be available at investor.natera.com.

About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer and organ transplantation including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Barbara Sullivan, Sullivan & Associates, 714-374-6174, bsullivan@sullivanpr.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/natera-to-host-investor-conference-call-to-discuss-strategic-roadmap-in-organ-transplantation-and-oncology-300670435.html

SOURCE Natera, Inc.

Shareholder Tools